This trial is conducted in Europe. The aim of this clinical trial is to investigate the blood glucose lowering effect of NN1250 (insulin degludec) in young and elderly subjects with type 1 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
27
0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
Novo Nordisk Investigational Site
Graz, Austria
Area under the glucose infusion rate curve during one dosing interval at steady state (for NN1250)
Time frame: 0-24 hours (derived on treatment day 6)
Area under the NN1250 concentration-time curve during one dosing interval at steady state
Time frame: 0-24 hours (derived on treatment day 6)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.